Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1
18+
2 sites in TX, UT
About this study
This Phase 1 study is focused on people with breast cancer. The primary outcome being measured is Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants with Dose-limiting Toxicity (DLT)
Secondary: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-last]) of EXS74539, Duration of Response (DoR), Maximum Concentration (Cmax) of EXS74539, Objective Response Rate (ORR), Overall Survival (OS), Progression-free Survival (PFS), Time to Cmax (tmax) of EXS74539
Oncology, Respiratory